Positive topline results have been announced from an open-label phase 2 clinical trial (Study ‘207’) evaluating VDPHL01, an oral minoxidil formulation, for women with mild-to-moderate pattern hair loss. 

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth, with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6.

The formulation utilises a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow. 

VDPHL01 is currently being evaluated in an extensive pivotal development programme designed to support its approval in both female and male pattern hair loss. 

There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years. The prevalence of pattern hair loss and the market demand for new treatments contribute to making it the largest aesthetics market worldwide, projected to reach approximately $30bn by 2028.

Pattern hair loss can have a significant impact on quality of life, affecting an individual’s mental health and relationships. People with pattern hair loss often experience depression, low self-esteem and social withdrawal. 

Veradermics, a dermatologist-founded, late-stage biopharmaceutical company, is focused on developing innovative therapeutics for androgenetic alopecia, a condition that affects an estimated 30 million women and 50 million men in the US. 

The company anticipates topline results of ‘Study 306’, a phase 2/3 clinical trial evaluating VDPHL01 in female pattern hair loss, in the first half of 2027. If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients.